To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Board members and management in Initiator Pharma exercise warrants
Initiator Pharma A/S (INIT) today announces that individuals in the board and managemet exercise a total of 434 197 warrants for subscription of new shares, raising approx 1,9 SEKM in proceeds to the company. The number of issued shares increases by 434 197 and the share capital increases by 45 590,685 DKK.
Initiator Pharma reports positive Phase IIa clinical data for IPED2015 in patients with severe Erectile Dysfunction
Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of erectile dysfunction (ED), today announced statistically significant results on key efficacy endpoints in severe ED patients after a single administration of IPED2015. Moreover, no observations of critical adverse events were recorded.
Initiator Pharma: INITIATOR PHARMA: Q3 2019 report
Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016….
Initiator Pharma receives extension of the option agreement for IP2018 from Saniona.
Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction, today announced that they have received an extension of the option agreement for the IP2018 drug candidate from Saniona until 31 March 2020 and furthermore opt to pay back the 5 MSEK bridge loan obtained earlier this year.
Initiator Pharma starts dosing of last the patients in the IPED2015 Clinical Trial
Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction, today announced that the dosing of the last patients in clinical Phase 2a Proof-of-Concept trial with IPED2015 has started. The study data analysis will be initiated shortly and our current best estimate for releasing draft data from the study is during December 2019.
Initiator Pharma receives commitment of support for IPED2015 from Innovation Fund Denmark
Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction, today announced that they have received a commitment from Innovation Fund Denmark to support the on-going clinical development of IPED2015.
Initiator Pharma: H1 2019 report
Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016….
Initiator Pharma A/S secures bridge financing in preparation of a clinical phase 2a trial for the candidate drug IP2018
Initiator Pharma A/S (“Initiator Pharma”) is currently conducting a clinical phase 2a trial for the company’s main candidate IPED2015, which is intended to be completed later in the summer. Initiator Pharma is now able to announce that the company has secured bridge financing of SEK 5 million with the aim pf preparing the company’s other candidate drug IP2018 for the start of a clinical phase 2a trial. With this bridge financing, the company is able to conduct activities for added value before seeking more long-term funding. The clinical phase 2a trial regarding IP2018 is expected to begin in early 2020.
Initiator Pharma provides an update on Phase 2a progress
Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction, today announced that the Phase 2a clinical study of IPED2015 in patients with Erectile Dysfunction is progressing well although recruitment of patients is taking slightly longer than planned. The reason for the slower recruitment is due to the aim of only including the right medically qualified and motivated patients for the trial. This delay will alter the date for the final dosing of patients in the Phase 2a, and our current best estimate for releasing draft data from the study is early Q4.